Doing Things Differently
Partner with YARAL Pharma
Innovation, Quality, and Growth in U.S. Generics
YARAL Pharma is redefining success in the U.S. generics market by combining IBSA Group’s global innovation with a modern, partnership-driven approach. We focus on the right products, built with the right partners, to deliver differentiated generics that drive growth.
Innovation Through Partnership
YARAL Pharma actively partners with companies that share our commitment to innovation, quality, and sustainable business growth. With expertise across all commercial channels, we continually pursue strategic partnerships and targeted acquisitions that expand access to differentiated products.
Commercial
Expertise
Portfolio
Development
Commercial Expertise
Since launching its first product in 2023, YARAL has gained traction, expanded its portfolio, and quickly become one of IBSA Group’s highest-performing subsidiaries and a key driver of the Group’s strategic initiatives.
YARAL is a dependable partner, known for its quality, reliable supply chain, and commitment to delivering consistent value to customers.
Portfolio Development
We’re Seeking:
- 505(b)(2), 505(j), ANDA, and authorized generics
- Co-development and co-marketing opportunities
- Complex generics leveraging novel delivery technologies with a high barrier to entry
- Therapeutic Focus Areas: pain, endocrinology, reproductive medicine, dermatology, rheumatology, and ophthalmology—targeted areas where YARAL leverages value-added technologies and unique delivery systems to address specific patient needs.
Your Partner for Growth, Innovation, and Reliability
Global Expertise
U.S. generics arm of Lugano, Switzerland-based IBSA Group with a legacy of innovation
Technology Advantage
Portfolio of proprietary drug-delivery technologies, including orally dissolving films, softgel capsules, topical patches, and other differentiated platforms
Integrated Development & Regulatory Expertise
Differentiated drug-delivery platforms supporting market-ready 505(b)(2), 505(j), and complex generics
Proven Commercial Partner
95%+ on-time, in-full delivery* with rapid growth across the IBSA Group; in just three years since launch, YARAL has become IBSA’s third highest-performing subsidiary
Doing Things Differently
In today’s competitive healthcare landscape; this shapes how YARAL rethinks stakeholder engagement, builds purposeful partnerships, and raises awareness through innovative communication
Flexible Partnerships
Co-development, private label, acquisition models
Private Label Solutions
We’re Offering:
- OTC & Rx private label products
- Differentiated technology-enabled products including, but not limited to, IBSA’s FilmTec™ and PEARLTec™ platforms.
- A range of dosage forms, such as topical patches, softgel capsules, and orally dissolving films
- Rapid market entry with scalable, flexible solutions—enabling SKU expansion, reliable raw material forecasting, and integrated supply support.
- Multichannel Approach – expanding access across multiple channels including retail, institutional, government, and telehealth – enabling partners to reach more patients while delivering measurable impact.
Meet the YARAL Pharma BD Team in 2026
| SHOW | LOCATION | DATE | |
|---|---|---|---|
| DCAT | New York, NY | March 23-26 | Schedule Meeting |
| CPHI USA | Philadelphia, PA | June 2-4 | Schedule Meeting |
| CPHI World Wide | Milan, Italy | October 6-8 | Schedule Meeting |
YARAL Pharma is expanding its portfolio and actively seeking new partnerships.
Use the form below to submit your opportunity or contact us directly:
YARAL Pharma’s Business Development Team:
YARAL Pharma Inc.
8 Campus Drive, Suite 201A
Parsippany, NJ 07054 USA
Phone: 908-632-6895
BD@yaralpharma.com
* Source: Supply chain performance data, 2025.